Sentinel node biopsy is currently considered to be an outstanding advance in surgical oncology and represents significant evolution toward minimally invasive breast cancer surgery. Detected by blue dye, radiopharmaceutical or combined techniques, the sentinel lymph node can be selectively used for the detection of micrometastasis through extensive histopathologic analysis. Nevertheless, before considering the sentinel lymph node concept as a new standard of care, the standardization of both detection methods and histopathological protocols is of critical importance. The future of this attractive technique is strictly dependent on the quality of teaching, training and evaluation in prospective controlled multicentric studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1024/1023-9332.5.5.214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Photoacoustic Imaging with Attention-Guided Deep Learning for Predicting Axillary Lymph Node Status in Breast Cancer.
Acad Radiol
January 2025
Department of Ultrasound, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen 518020, Guangdong, China (G.L., S.T., Z.H., M.W., S.M., J.X., F.D.); Department of Ultrasound, The First Affiliated Hospital, Southern University of Science and Technology (Shenzhen People's Hospital), Shenzhen 518020, Guangdong, China (H.T., H.W., J.X., F.D.). Electronic address:
Rationale And Objectives: Preoperative assessment of axillary lymph node (ALN) status is essential for breast cancer management. This study explores the use of photoacoustic (PA) imaging combined with attention-guided deep learning (DL) for precise prediction of ALN status.
Materials And Methods: This retrospective study included patients with histologically confirmed early-stage breast cancer from 2022 to 2024, randomly divided (8:2) into training and test cohorts.
Predictors of Sentinel Lymph Node Biopsy in Thin Melanoma: Understanding the Impact of the American Joint Commission on Cancer 8th Edition Staging System.
J Am Coll Surg
January 2025
The Hiram C. Polk Jr., MD Department of Surgery, University of Louisville, Louisville, KY.
Background: The definition of T1b cutaneous melanoma was changed in the 8th edition of the AJCC staging system based on survival differences but not risk of sentinel lymph node (SLN) metastases. We sought to evaluate changes in SLN biopsy (SLNB) use and rates of positive SLNB in response to updated staging criteria, and to evaluate the incidence of high-risk features in T1a melanoma in whom SLNB is now recommended.
Study Design: The 2021 National Cancer Database Melanoma PUF was used to obtain SLNB utilization and positivity rates in T1 (thin) melanoma (thickness ≤1.
ASO Visual Abstract: Magnetic Sentinel Lymph Node Biopsy in Early Breast Cancer Patients: An Individual Patient Data Meta-Analysis of Tracer Uptake.
Ann Surg Oncol
January 2025
Magnetic Detection and Imaging Group, Technical Medical Centre, University of Twente, Enschede, The Netherlands.
External Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema.
JAMA Netw Open
January 2025
Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Importance: Secondary lymphedema is a common, harmful side effect of breast cancer treatment. Robust risk models that are externally validated are needed to facilitate clinical translation. A published risk model used 5 accessible clinical factors to predict the development of breast cancer-related lymphedema; this model included a patient's mammographic breast density as a novel predictive factor.
View Article and Find Full Text PDFMelanoma: Assessment and Management summary of 2022 update of the NICE guidelines.
Br J Dermatol
January 2025
Research fellow and General surgery trainee, Royal Marsden Hospital, London, UK.
Melanoma is the fifth most common skin cancer in the UK, accounting for 4% of all new cancer cases, with a predicted 7% increase in incidence between 2014-35. In parallel, since the initial publication of the Melanoma NICE Guidelines in 2015, there has been a paradigm shift in the management of the disease, with the introduction of effective systemic therapies. These innovations have reshaped the management of melanoma throughout the patient journey, and improved clinical outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!